

Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole to its Board of Directors

Friendswood, Texas – December 6, 2018 – Castle Biosciences, Inc., a skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the appointment of G. Bradley Cole to its Board of Directors.

Mr. Cole brings over 30 years of successful finance and operations leadership in the diagnostics and life sciences industries. Currently he is Chief Financial Officer of Genomic Health, a leading provider of genomic-based diagnostic tests, where he has been influential in steering the company through its initial public offering, growth and profitability, and international expansion. From 2009 through 2018, Mr. Cole served as both Chief Operating Officer and Chief Financial Officer at Genomic Health. Before joining Genomic Health, he was Vice President, Finance and Business Development for the Endovascular Solutions Group at Guidant Corporation, a designer and developer of cardiovascular medical products. Prior to that, he served as Vice President and General Manager of the Vascular Surgery Business Unit of Guidant. Previously he was Chief Financial Officer at Endovascular Technologies, Inc., a publicly traded medical device company acquired by Guidant Corporation in 1997, and Chief Financial Officer at Applied Biosystems, a publicly traded life sciences company until 1994.

“Brad Cole brings exceptional financial acumen and vision to our Board of Directors,” said Dan Bradbury, Chairman of the Board of Castle Biosciences. “He has been instrumental to the success of an industry-leading public company, and we anticipate that his experience will help drive strategic growth at Castle Biosciences to address the increasing patient need for our dermatologic cancer testing services.”

In 2017, Mr. Cole was recognized for his leadership and named Bay Area CFO of the Year by the San Francisco Business Times. He has been a member of the Biola University Board of Trustees since 2002. He holds a B.S. in business from Biola University and an M.B.A. from San Jose State University.

About Castle Biosciences

Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about treatment and follow up care based on the individual molecular signature of the patient’s tumor. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx[®]-Melanoma, DecisionDx[®]-CMSeq; www.SkinMelanoma.com) and uveal melanoma (DecisionDx[®]-UM, DecisionDx[®]-PRAME and DecisionDx[®]-UMSeq; www.MyUvealMelanoma.com), with programs in development for other underserved cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. More information can be found at www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.

Contact

Derek Maetzold, President and CEO

866-788-9007

IR@castlebiosciences.com